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Objective: It has recently been proposed that nitric oxide synthase, in the presence
of suboptimal levels of tetrahydrobiopterin, an essential cofactor of this enzyme,
might favor increased production of oxygen radicals. The aim of this study was to
clarify whether supplement with tetrahydrobiopterin would exert a cardioprotective
effect against ischemia-reperfusion injury.
Methods: Isolated perfused rat hearts were subjected to 30 minutes of global
ischemia and 30 minutes of reperfusion at 37°C. Hearts were treated with tetrahy-
drobiopterin or vehicle for 5 minutes just before ischemia and during the first 5
minutes of the reperfusion period. Effects of tetrahydrobiopterin on left ventricular
function, myocardial contents of lipid peroxidation and high-energy phosphates, and
levels of lactate dehydrogenase and nitrite plus nitrate in perfusate during ischemia
and after reperfusion were estimated and further compared with those of superoxide
dismutase plus catalase or L-ascorbic acid.
Results: Tetrahydrobiopterin and superoxide dismutase plus catalase both improved
contractile and metabolic abnormalities in reperfused hearts. On the other hand,
L-ascorbic acid at a dose having an equipotent radical scavenging activity with
tetrahydrobiopterin did not significantly affect the postischemic changes. Although
tetrahydrobiopterin and superoxide dismutase plus catalase significantly alleviated
ischemic contracture during ischemia, diminished perfusate levels of nitrite plus
nitrate after reperfusion were restored only with tetrahydrobiopterin.
Conclusion: Results demonstrated that tetrahydrobiopterin lessens ischemia-reper-
fusion injury in isolated perfused rat hearts, probably independent of its intrinsic
radical scavenging action. The cardioprotective effect of tetrahydrobiopterin implies
that tetrahydrobiopterin could be a novel and effective therapeutic option in the
treatment of ischemia-reperfusion injury.
Nitric oxide (NO) plays a role in the regulation of vascular tone andthe maintenance of vascular integrity.1 Cardiovascular diseases,such as hypercholesterolemia, diabetes, and hypertension, arecharacterized by endothelial dysfunction and reduced endotheli-um-mediated vasodilatation.2 The underlying defect might in-volve both decreased formation and increased breakdown of NO
by means of reaction with superoxide anion.
The availability of tetrahydrobiopterin (BH4) is essential for the catalytic activity
of NO synthase (NOS).3 A close link between cellular availability of BH4 and NO
synthesis has recently been demonstrated in a number of different cell types.4,5
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Biochemical evidence revealed that activation of purified
constitutive NOS in the presence of suboptimal levels of
BH4 results in uncoupling of oxygen reduction and arginine
oxidation.6 In agreement with these results, Cosentino and
Katusic7 recently proposed that, in isolated canine coronary
arteries depleted of BH4, endothelial NOS might serve as a
source of oxygen free radicals (OFRs). Furthermore, in
human aortic endothelial cells exposed to prolonged stretch-
ing, inhibition of BH4 synthesis has been shown to increase
markedly the production of superoxide anion.8 In addition,
Pritchard and colleagues9 found that increased generation of
superoxide anion in cultured endothelial cells exposed to
low-density lipoprotein can be inhibited by NG-nitro-L-ar-
ginine methyl ester, a selective inhibitor of NOS. These
results indicate that NOS itself can be a potential source for
endothelial production of OFRs and that decreased avail-
ability of BH4 might cause a shift in balance between
production of protective NO and toxic OFRs.6 Such an
imbalance, in turn, could result in endothelial dysfunction
and oxidative vascular injury, as described in a number of
vascular diseases.1,2
Accordingly, these findings lead to the hypothesis that
such dysfunctional NOS caused by insufficiency of BH4
participates in oxidative injury, especially under pathologic
conditions, including ischemia and reperfusion. In fact, ad-
ministration of exogenous BH4 has been shown to reduce
postischemic endothelial dysfunction,10 posttransplantation
lung edema and OFR injury in grafts,11 and ischemic renal
injury.12 Moreover, a recent experimental study suggested
that intracellular BH4 levels are reduced after ischemia and
reperfusion.10
Thus, in the present study the major purpose was to
clarify whether BH4 would exert a beneficial effect in a
model of myocardial ischemia-reperfusion injury. The ef-
fects of administration of BH4 on myocardial ischemia-
reperfusion injury were examined in isolated rat hearts by
using the Langendorff method and compared with those of
the representative antioxidants superoxide dismutase plus
catalase (SOD/catalase)13 and L-ascorbic acid (Vit C)14 be-
cause BH4 itself has been reported to have radical scaveng-
ing activity, as assessed by means of spin trapping electron
spin resonance (ESR) spectrometry in vitro.15
Materials and Methods
The animals used in this study were handled in accordance with
the Guidelines for Animal Experimentation of the University of
the Ryukyus, and the experimental protocol was approved by the
Animal Care Committee of this institution.
In Vitro Free Radical Scavenging Action of BH4
The free radical quenching capacity of BH4 in vitro was tested by
using the method of breaching the stable radical 1,1-diphenyl-2-
picrylhydrazyl (DPPH) with a free radical monitor (JES-FR 30;
JEOL, Tokyo, Japan). The reaction mixture contains 100 L of
BH4 or water and 100 L of 0.2 mmol/L DPPH. ESR spectra were
measured by calculating the relative peak height of DPPH com-
pared with that of the internal standard manganese oxide. Vit C
was used as a standard agent for comparison of radical scavenging
activity. BH4 and Vit C decreased the ESR spectra of DPPH in a
concentration-dependent manner. The concentrations of BH4 and
Vit C required to quench DPPH radicals by 50% were 46.0 and
32.0 mol/L, respectively.
Experimental Preparation
Male Sprague-Dawley rats (SLC, Shizuoka, Japan) weighing 260
to 310 g were anesthetized with diethylether and given 1000 IU/kg
body weight sodium heparin intravenously. After thoracotomy, the
heart was rapidly excised. Then the ascending aorta was cannu-
lated, and retrograde perfusion of the heart was initiated on a
Langendorff apparatus at a constant pressure of 100 cm H2O. The
isolated heart was perfused with 37°C Krebs-Henseleit solution
(KHS) of the following composition: NaCl, 120 mmol/L; KCl, 4.8
mmol/L; CaCl2, 1.25 mmol/L; MgSO4, 1.2 mmol/L; KH2PO4, 1.2
mmol/L; NaHCO3, 25.0 mmol/L; and glucose, 11.0 mmol/L. The
perfusate was oxygenated with 95% O2/5% CO2 (PO2 600 mm
Hg).
A thin-wall latex balloon was inserted into the left ventricle
through the left atrium to monitor left ventricular pressure (LVP).
The balloon was filled with bubble-free saline. The ventricle was
loaded with 5 to 10 mm Hg of the initial left ventricular end-
diastolic pressure (LVEDP), and this balloon volume was main-
tained throughout the experiments. LVP was measured with a
pressure transducer (TP-400T; Nihon Kohden, Tokyo, Japan), and
the first derivative (dp/dt) of LVP was derived from differentiating
the signal of LVP with an electronic differentiator (ED-601G,
Nihon Kohden). Left ventricular developed pressure (LVDP) was
estimated from left ventricular systolic pressure and LVEDP. The
mean coronary flow (CF) was measured with an electromagnetic
flow probe (FF-030T, Nihon Kohden) attached to the aortic can-
nula, which was connected to an electromagnetic flowmeter
(MFV-3200, Nihon Kohden). Heart rate was counted by using a
cardiotachometer (AT-600G, Nihon Kohden) triggered by the
pressure pulse. After 10 minutes of equilibration, the hearts were
atrially paced throughout the experiments with an electronic stim-
ulator (SEN-3301, Nihon Kohden). Pacing rate was set at 110% of
the own beat during the stabilizing period of Langendorff perfu-
sion. All hemodynamic parameters were continuously recorded on
an 8-channel thermal-pen recorder (WT-685G, Nihon Kohden).
Experimental Protocol
All hearts were perfused for 10 minutes to stabilize hemodynamics
before the experiment was started. Five minutes after the begin-
ning of atrial pacing, baseline values of cardiovascular parameters
were measured.
The hearts were divided into nonischemic and ischemic groups
and were infused with vehicle (nonischemic KHS group and
ischemic KHS group, n  8 each) or BH4 (nonischemic BH4
group, ischemic BH4 group, and ischemic low BH4 group, n  8
each). BH4 (0.6 or 1.25 mg/mL) and vehicle (KHS) were infused
through a 3-way cock placed just proximal to the aortic cannula by
using an infusion pump (Model 11 or 22; Harvard Apparatus Co,
Holliston, Mass) at an infusion rate of 0.4 mL/min for 5 minutes
Cardiopulmonary Support and Physiology Yamashiro et al
776 The Journal of Thoracic and Cardiovascular Surgery ● October 2002
CSP
just before ischemia and then again during the first 5 minutes of the
reperfusion period. The dosages of BH4 in coronary perfusate
(corresponding to nearly 50 and 100 mol/L, respectively) used in
this study were determined considering the previous in vitro find-
ings that concentration-dependent NO production, which was es-
timated as L-citrulline formation, by human endothelial NOS was
observed at doses of BH4 ranging from 10 to 100 mol/L.16
The hearts of rats from the ischemic groups were subjected to
global ischemia (cessation of flow) at 37°C for 30 minutes, ac-
cording to the method of Takeo and colleagues17; the ischemic
hearts were submerged in a chamber filled with the KHS, which
was equilibrated with a gas mixture of 95% N2/5% CO2 (partial
pressure of O2 10 mm Hg) to support global ischemia and
maintained at 37°C to prevent hypothermia-induced cardioprotec-
tion. During ischemia, peak LVEDP and the time to onset of
ischemic contracture for LVEDP to increase more than 5 mm Hg
were measured. After completion of ischemia, the KHS in the
chamber was drained, and the hearts were reperfused with an
aerobic KHS for 30 minutes. Sampling of perfusate was performed
before ischemia (baseline) and at 10, 20, and 30 minutes after the
initiation of reperfusion, and samples were stored at 20°C for
measurement of lactate dehydrogenase (LDH) activity and nitrite
plus nitrate (NOx) level.
The hearts of rats from the nonischemic groups were paced and
perfused without ischemia. BH4 (1.25 mg/mL, nonischemic BH4
group) or vehicle (nonischemic KHS group) infusion and sampling
of perfusate were performed in the same time course as for the
ischemic groups. A low dose (0.6 mg/mL) of BH4 in the nonisch-
emic group was omitted because there were no significant changes
in functional and metabolic parameters with high-dose (1.25 mg/
mL) BH4 in the preliminary experiment.
At the end of the experiments, sections of the left ventricular
(LV) free wall were quickly excised and frozen with liquid nitro-
gen. These frozen myocardial sections were applied for determi-
nation of lipid peroxides and energy metabolites in myocardial
tissues. Additionally, the effects of SOD (2000 U/mL) plus cata-
lase (2000 U/mL; SOD/catalase group, n  8) and Vit C (Vit C
group, n 6) at a dose (0.49 mg/mL) having an equipotent radical
scavenging activity in vitro with BH4 (1.25 mg/mL) on myocardial
ischemia-reperfusion injury were evaluated in the same time
course as mentioned above.
In addition, effects of BH4 (2.5 mg/mL for 5 minutes) admin-
istered only just before ischemia (pre-BH4 group, n  8) were
compared with those of BH4 administered only during the first 5
minutes of the reperfusion period (post-BH4 group, n  8) to
estimate whether the time for BH4 treatment would influence the
effects of BH4 on myocardial ischemia-reperfusion injury.
Determination of Myocardial Energy Metabolites
The frozen myocardial tissue for measurement of energy metabo-
lites was lyophilized for 6 hours. The dried tissue was homoge-
nized with 0.6 mol/L perchloric acid. The mixture was centrifuged
at 12,000 rpm for 15 minutes at 2°C, and the supernatant was used
for assay. Adenosine triphosphate (ATP) was determined by using
the firefly luminescence method with an ATP monitoring agent
(LL-100-2; Toyo Ink, Tokyo, Japan) and a lumiphotometer (Mini-
lumat LB9506; Berthold GmbH & Co KG, Calmabacher, Germa-
ny). Creatine phosphate (CrP) and inorganic phosphate (Pi) levels
were determined by using the method of Fiske and Subbarow, as
modified by Furchgott and DeGubareff,18 with a spectrophotom-
eter (UV-150-02; Shimadzu, Kyoto, Japan).
Determination of Myocardial Tissue Lipid
Peroxidation
The extent of lipid peroxidation in the frozen myocardial tissue
was measured by using the thiobarbituric acid (TBA) method,19
with some modifications. The amount of TBA-reactive substances
was estimated as malondialdehyde (MDA) equivalents per gram of
wet myocardial weight. The developed color was read with a
spectrophotometer (UV-2200A, Shimadzu) at 532 nm. Commer-
cially available 1,1,3,3-tetraethoxypropane was used as a standard.
Determination of LDH Activity in the Effluent
LDH activity in the coronary effluent was estimated by using the
method of Wro´blewski and La Due20 with an LDH monitoring kit
(Wako Pure Chemical, Osaka, Japan) and a spectrophotometer
(UV-2200A) at 340 nm.
Determination of NOx Level in the Effluent
NOx levels before ischemia and 10 minutes after the initiation of
reperfusion in the effluent were analyzed by using the Griess
















Non-KHS (n  8) 347.5 2.5 99.1 2.0 5.3 0.3 93.5 2.1 4018.8 84.5 2106.3 55.5 14.1 0.5
Non-BH4 (n  8) 347.5 2.5 100.0 2.1 5.4 0.4 94.6 1.9 3987.5 89.5 2081.3 54.2 15.1 0.7
Isc KHS (n  8) 347.5 2.5 101.0 2.5 6.3 0.4 94.8 2.6 4118.8 121.7 2212.5 66.6 13.0 0.9
Isc BH4 (n  8) 347.5 2.5 102.5 1.9 5.6 0.4 96.9 1.9 4031.3 54.2 2206.3 44.8 14.8 0.9
Isc low BH4 (n  8) 347.5 2.5 101.6 2.5 6.0 0.4 95.6 3.4 4118.8 71.3 2168.8 67.4 14.8 0.8
Vit C (n  6) 346.7 3.3 101.7 2.1 5.3 0.3 96.3 2.1 3858.3 96.1 2083.3 96.3 14.0 1.1
SOD/catalase (n  8) 342.5 3.7 104.4 1.7 5.9 0.4 98.5 1.6 3912.5 90.0 2281.3 136.3 14.3 0.9
All values are expressed as means  SE. There were no significant differences among groups.
HR, Heart rate; LVsP, left ventricular systolic pressure; non-KHS, nonischemic KHS; non-BH4, nonischemic BH4 (1.25 mg/mL); isc KHS, ischemic KHS; isc
BH4, ischemic BH4 (1.25 mg/mL); isc low BH4, ischemic low BH4 (0.6 mg/mL); Vit C, Vit C (0.49 mg/mL); SOD/catalase, superoxide dismutase plus catalase
(2000 U/mL each).
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method with an automated NO detector high-performance liquid
chromatography system (ENO-20; EICOM, Kyoto, Japan). In the
nonischemic groups the NOx level in the effluent was analyzed in
the same time course as for the ischemic groups. The absorbance
of the color of the product dye at 540 nm was measured. Appro-
priate concentrations of NaNO2 and NaNO3 were used for con-
structing a standard curve. The time-voltage change was traced by
using a data processor (EPC-300, EICOM). By comparing a peak
area shown on a chromatogram with a standard area, the concen-
tration of NOx in the effluent was determined. The detection limit
in this assay is 10 pmol/mL, according to the manufacturer.
Drugs
The drugs used in this study were (6R)-5,6,7,8-tetrahydro-L-biop-
terin dihydrochloride (BH4, Wako), bovine erythrocyte SOD
(5100 U/mg; Sigma Chemical Co, St Louis, Mo), bovine liver
catalase (3260 U/mg, Sigma), Vit C (Wako), DPPH (Wako), TBA
(Sigma), 1,1,3,3-tetraethoxypropane (Sigma), NaNO2 (Wako), and
NaNO3 (Wako).
BH4, Vit C, SOD, and catalase were dissolved in KHS just
before use. Vit C, at a concentration used in this study, caused no
change in pH of coronary effluent.
Data Analysis
The data were analyzed by using 1-way analysis of variance, and
paired and unpaired observations were analyzed with paired and
unpaired t tests, respectively. All values are presented as means 
SE.
Results
Effect of BH4 on LV Function
Baseline values of cardiovascular parameters, such as heart
rate, LV systolic pressure, LVEDP, LVDP, maximum and
minimum LV dp/dt, and CF were similar in all groups
(Table 1). Infusion (0.4 mL/min for 5 minutes) of KHS and
BH4 caused virtually no changes in all measured cardiovas-
cular parameters before ischemia in ischemic groups and
Figure 1. Time course of changes in LVDP (A), mean CF (B), maximum LV dp/dt (C), and minimum LV dp/dt (D) in
the nonischemic KHS group (n  8, open triangles), the nonischemic BH4 group (n  8, filled triangles), the
ischemic KHS group (n 8, open circles), the ischemic BH4 (1.25 mg/mL) group (n 8, filled circles), the ischemic
low BH4 (0.6 mg/mL) group (n  8, open diamonds), the Vit C (0.49 mg/mL) group (n  6, filled diamonds), and the
SOD/catalase (2000 U/mL each) group (n  8, open squares). Values are expressed as percentages of correspond-
ing baseline values. Each value represents mean  SE. ***P < .001 versus ischemic KHS group.
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throughout the experiments in nonischemic groups (Figure
1).
During 30 minutes of ischemia, LVDP, maximum and
minimum LV dp/dt, and CF immediately decreased to al-
most null in all ischemic groups, and during 30 minutes of
reperfusion, these parameters showed partial recoveries
(Figure 1). Significantly better recoveries of LVDP and
maximum and minimum LV dp/dt during reperfusion were
observed in ischemic BH4 (0.6 and 1.25 mg/mL) groups
than those in the ischemic KHS group in a dose-related
manner, whereas CF was comparable among these 3 groups
(Figure 1). LVEDP of vehicle (KHS)–treated hearts in-
creased during ischemia and increased again immediately
after the onset of reperfusion (Figure 2, A). The increases in
LVEDP during reperfusion in the ischemic BH4 and isch-
emic low-BH4 groups were significantly smaller than those
in the ischemic KHS group (Figure 2, A). In addition, in the
ischemic BH4 and ischemic low-BH4 groups, significantly
delayed onset of ischemic contracture and lowered maximal
values of LVEDP during ischemia were seen in comparison
with the corresponding values in the ischemic KHS group
(Figure 2, B and C). Likewise, SOD/catalase significantly
improved contractile dysfunction and attenuated increases
in LVEDP both during ischemia and reperfusion (Figures 1
and 2). On the other hand, in Vit C–treated ischemic hearts,
changes in LVDP and LV dp/dt during reperfusion were
indistinguishable from those in vehicle (KHS)–treated isch-
emic hearts (Figure 1), although increases in LVEDP during
ischemia were significantly attenuated (Figure 2).
Metabolic Changes
Table 2 shows changes in the energy metabolism in the LV
free wall at 30 minutes of reperfusion. In nonischemic
hearts with infusion of KHS, myocardial contents of ATP,
Figure 2. Time course of change in LVEDP (A), time to onset of ischemic contracture (B), and peak LVEDP during
ischemia (C). Each value represents mean  SE. *P < .05, **P < .01, and ***P < .001 versus ischemic KHS group.
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CrP, and Pi were 30.3  3.6, 17.7  1.2, and 32.9  1.7
mol/g dry myocardial tissue weight, respectively, which
should reflect the state of myocardial oxidative metabolism.
Myocardial contents in these energy metabolites in the
nonischemic BH4 group were similar to those in the non-
ischemic KHS group. In vehicle (KHS)–treated ischemic
hearts, ATP and CrP markedly decreased, and Pi markedly
increased. On the other hand, levels of the high-energy
phosphates ATP and CrP and Pi levels in both the ischemic
BH4 and SOD/catalase groups were significantly higher or
lower than those in the ischemic KHS group, respectively,
whereas these myocardial levels in the Vit C group were
comparable with those in the ischemic KHS group.
Myocardial content of MDA in the ischemic KHS group
increased significantly when compared with contents in
nonischemic hearts (Table 2). On the other hand, in isch-
emic BH4 and SOD/catalase groups, but not in the Vit C
group, the MDA contents were significantly lower than that
in the ischemic KHS group and showed nearly the same
contents as those in nonischemic groups.
In all groups the LDH activities in the coronary effluent
before ischemia were minimal, and those in nonischemic
groups were unchanged throughout experiments (Figure 3).
Release of LDH into the effluent in the ischemic KHS group
was significantly increased after ischemia, but the LDH
releases in the ischemic BH4 and ischemic low-BH4 groups
Figure 3. LDH activity in coronary effluent in the nonischemic KHS group (n  7), the nonischemic BH4 group (n 
7), the ischemic KHS group (n  7), the ischemic BH4 group (n  7), the ischemic low BH4 group (n  7), the Vit
C group (n  6), and the SOD/catalase group (n  8). Each value represents mean  SE. NS, No significant
difference. ***P < .001 versus ischemic KHS group; †P < .05 and †††P < .001 versus nonischemic KHS group.
TABLE 2. Energy metabolites and MDA contents in myocardial tissue
Group
ATP
(mol/g dry tissue weight)
CrP
(mol/g dry tissue weight)
Pi
(mol/g dry tissue weight)
MDA
(nmol/g wet tissue weight)
Non-KHS (n  8) 30.3 3.6‡ 17.7 1.2† 32.9 1.7‡ 185.8 14.3†
Non-BH4 (n  8) 28.8 3.3‡ 17.1 1.4† 34.9 2.3‡ 189.3 13.7†
Isc KHS (n  8) 4.0 1.2¶ 10.1 1.2 62.2 4.9¶ 252.9 17.9
Isc BH4 (n  8) 12.7 1.2†¶ 17.7 1.6† 45.0 3.7‡ 191.6 10.2†
Isc low BH4 (n  8) 10.6 1.4¶ 14.5 1.9* 52.3 4.8* 207.9 19.8*
Vit C (n  6) 5.7 1.2¶ 6.3 1.2¶ 53.7 2.8¶ 249.7 7.6§
SOD/catalase (n  8) 12.4 1.6†¶ 17.3 2.2* 46.9 2.6† 193.3 20.1†
All values are expressed as means  SE. Non-KHS, Nonischemic KHS; non-BH4, nonischemic BH4 (1.25 mg/mL); isc KHS, ischemic KHS; isc BH4, ischemic
BH4 (1.25 mg/mL); isc low BH4, ischemic low BH4 (0.6 mg/mL); Vit C, Vit C (0.49 mg/mL); SOD/catalase, superoxide dismutase plus catalase (2000 U/mL each).
*P  .05, †P  .01, ‡P  .001 versus ischemic KHS group.
§P  .05, P  .01, ¶P  .001 versus nonischemic KHS group.
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and the SOD/catalase group were significantly lower than
that in the ischemic KHS group throughout reperfusion
(Figure 3). Moreover, LDH release in the Vit C (0.49
mg/mL) group was similar to that in the ischemic KHS
group, and a higher dosage (4.9 mg/mL) of Vit C also did
not alter postischemic functional and metabolic abnormali-
ties (n  4, data not shown).
NOx Level in the Coronary Effluent
Baseline values (before ischemia) of NOx in the coronary
effluent were not different among all groups (Table 3). In
the nonischemic BH4 group, as well as in the nonischemic
KHS group, NOx levels at the corresponding time to 10
minutes after reperfusion were similar to the baseline val-
ues. In the ischemic KHS group the level of NOx at 10
minutes after reperfusion markedly decreased from 340.6
68.5 pmol/mL (before ischemia) to 76.9  16.7 pmol/mL.
As shown in Figure 4, the NOx level in the ischemic BH4
group 10 minutes after reperfusion (75.0%  9.4%), which
is expressed as the percentage of the value before ischemia
(379.0  79.1 pmol/mL), was significantly higher than that
in the ischemic KHS group (31.1%  9.4%, P  .001). On
the other hand, low-dose BH4, SOD/catalase, and Vit C did
not significantly improve the NOx level after ischemia
(Figure 4).
Comparison of the Effect of BH4 Administered Before
Ischemia and That Administered After Ischemia
Treatment with BH4 only before ischemia significantly im-
proved contractile dysfunction and attenuated decreases in
ATP content and increases in LDH release (Table 4). On the
other hand, treatment with BH4 only after ischemia did not
alter the ischemia and reperfusion–induced functional and
metabolic abnormalities that were indistinguishable from
those in the ischemic KHS group (Table 4).
Discussion
In the present study administration of BH4, in contrast to its
vehicle (KHS), dose dependently alleviated myocardial
contractile dysfunction caused by 30 minutes of ischemia
followed by 30 minutes of reperfusion at 37°C. Moreover,
BH4 also attenuated increases in lipid peroxidation esti-
mated as the amount of MDA equivalents, decreases in ATP
content, and increases in LDH release, an index of cardiac
cell membrane damage, in the reperfused hearts. Increases
in the tissue MDA level have been observed in such con-
ditions that OFR-mediated damage is implicated.21 Further-
more, it is well known that both the mechanical function of
the heart and myocardial energy metabolism are markedly
impaired after ischemia. Consequently, the present results
clearly indicate that BH4 exerts cardioprotective actions
against postischemic injury in rat perfused hearts. In non-
ischemic hearts, on the other hand, BH4 did not alter any
measured cardiovascular parameters and biochemical in-
dexes. The lack of the coronary vasodilating action of BH4
at doses used in this study under the aerobic condition is
consistent with previous findings,22 although there is an in
vivo study with healthy volunteers reporting vasodilator
effects of intra-arterial BH4 infusion at much higher doses
(16 or 32 mg/min) in the forearm circulation.23 Thus, the
possibility that the observed favorable effects of BH4 would
be attributable to an improvement of coronary perfusion can
be ruled out.
In the present study BH4, as well as SOD/catalase, sup-
Figure 4. Percentage of NOx level in the coronary effluent after
ischemia. Values are expressed as percentages of corresponding
baseline values before ischemia. Each value represents mean 
SE. ***P < .001 versus ischemic KHS group; ††P < .01 and
†††P < .001 versus nonischemic KHS group.
TABLE 3. Baseline levels of NOx in the coronary effluent
Group NOx (pmol/mL effluent)
Non-KHS (n  8) 336.0 114.7
Non-BH4 (n  8) 295.9 66.8
Isc KHS (n  8) 340.6 68.5
Isc BH4 (n  8) 379.0 79.1
Isc low BH4 (n  8) 363.0 109.1
Vit C (n  6) 374.9 55.3
SOD/catalase (n  8) 358.5 56.8
All values are expressed as means  SE. There were no significant
differences in NOx levels in the coronary effluent before ischemia among
groups.
Non-KHS, Nonischemic KHS; non-BH4, nonischemic BH4 (1.25 mg/mL); isc
KHS, ischemic KHS; isc BH4, ischemic BH4 (1.25 mg/mL); isc low BH4,
ischemic low BH4 (0.6 mg/mL); Vit C, Vit C (0.49 mg/mL); SOD/catalase,
superoxide dismutase plus catalase (2000 U/mL each).
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pressed increases in LVEDP both during ischemia and
reperfusion. Additionally, the time to onset of ischemic
contracture in our BH4 or SOD/catalase groups was signif-
icantly longer than that in the ischemic KHS group. Isch-
emic contracture has been suggested to be a sign of irre-
versible cell damage, and its appearance is thought to
coincide with the time when glycolytic ATP production
ceases.24 Some studies with electron paramagnetic reso-
nance spectroscopy support the theory that OFRs are gen-
erated during myocardial ischemia in addition to reperfu-
sion.25 These findings suggest that the beneficial effects of
SOD/catalase are derived from scavenging of OFRs during
not only reperfusion but also ischemia. In this study admin-
istration of BH4 only before ischemia (pre-BH4 group)
improved postischemic contractile dysfunction in compari-
son with that seen in the post-BH4 group but to a lesser
extent than that seen in the group in which BH4 was ad-
ministered both before ischemia and just after reperfusion.
Therefore, it is likely that the improvements of reperfusion
injury by BH4 were derived from the effects of BH4 during
ischemia in addition to reperfusion.
Kojima and colleagues15 reported that BH4 has antioxi-
dant activities and protects against paraquat-induced injury
of rat hepatocytes, which is believed to be caused mainly by
generation of OFRs. They considered that BH4 acts directly
as a scavenger of superoxide anion generated by xanthine–
xanthine oxidase or by rat macrophage–phorbol myristate
acetate radical-generating systems. We also confirmed that
BH4 itself possesses in vitro free radical scavenging activity
with a similar potency to that of Vit C when compared on a
molecular basis. Nevertheless, Vit C at 0.49 mg/mL, which
was shown to have a radical scavenging activity equal to
that of BH4 (1.25 mg/mL), or even at 4.9 mg/mL failed to
improve ischemia and reperfusion–induced mechanical and
metabolic abnormalities, which is different from the case of
SOD/catalase or BH4. Because exogenous SOD, as well as
catalase, is impermeable to the cell membrane because of its
large molecular size, scavenging OFRs elicited by SOD/
catalase leading to beneficial effects might occur solely in
the intravascular space. Thus, the reason for the lack of
cardioprotective effects of Vit C at doses used in this study
might be explained by insufficiency of the antioxidant ac-
tivity rather than by a poor membrane permeability. Con-
sidering these data, the free radical scavenging activity of
BH4 itself might play a minor role, if any, in the protective
effects against oxidative myocardial injury produced by 30
minutes of ischemia and 30 minutes of reperfusion at 37°C.
Va´squez-Vivar and coworkers26 reported that BH4 has a
protective effect against cerebral ischemia-reperfusion in-
jury through inhibiting the generation of superoxide anion
simultaneously with increasing levels of NO produced by
NOS. Similarly, several investigators have demonstrated
that treatment with BH4 reduces ischemia and reperfusion–
induced tissue injury10-12 and have suggested that decreased
TABLE 4. Comparison of the effect of BH4 administered before and after ischemia
Ischemic KHS group (n  8) Pre-BH4 group (n  8) Post-BH4 group (n  8)
Recoveries of contractile function
LVDP (%) 11.7 2.3 37.3 4.9‡¶ 13.3 3.5
CF (%) 67.6 2.5 63.4 1.4 64.8 2.8
Max LV dp/dt (%) 8.6 2.6 34.6 5.9† 8.8 2.8
Min LV dp/dt (%) 13.9 4.7 43.0 5.2‡¶ 11.1 3.5
Time to onset of ischemic contracture (min) 11.4 0.3 14.1 0.6‡¶ 11.6 0.2
Peak LVEDP (mm Hg) 103.1 5.1 73.8 4.4‡¶ 101.3 2.1
ATP (mol/g dry tissue weight) 4.0 1.2 8.5 1.1* 7.1 1.2
CrP (mol/g dry tissue weight) 10.2 1.2 11.2 1.3 9.7 1.0
Pi (mol/g dry tissue weight) 62.2 4.9 57.3 2.8 62.8 2.5
MDA (nmol/g wet tissue weight) 252.9 17.9 218.2 13.6 250.9 10.9
LDH (IU/L effluent)
Before ischemia 3.5 1.0 4.6 1.0 4.0 0.9
10 min after reperfusion 155.8 37.6 61.8 16.1* 134.1 22.4
20 min after reperfusion 122.5 24.7 43.7 12.6†§ 103.0 16.6
30 min after reperfusion 93.8 19.6 39.3 11.5* 73.1 21.2
NOx level (pmol/mL effluent)
Before ischemia 340.6 68.5 340.3 91.7 299.7 67.3
After ischemia 76.9 16.7 124.3 38.7 139.7 39.5
Percentage of the value before ischemia 31.1 9.4 53.9 12.2 43.9 7.0
The pre-BH4 group received BH4 (2.5 mg/mL) for 5 minutes only just before ischemia. The post-BH4 group received BH4 (2.5 mg/mL) only during the first
5-minute reperfusion period. The ischemic KHS group received vehicle (KHS) for 5 minutes just before ischemia and during the first 5-minute reperfusion
period. All values are expressed as means  SE. Recoveries of contractile function at 30 minutes of reperfusion are expressed as a percentage of
corresponding baseline value.
*P  .05, †P  .01, ‡P  .001 versus ischemic KHS group.
§P  .05, P  .01, ¶P  .001 versus post-BH4 group.
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endothelium-derived NO activity might worsen the isch-
emic tissue damage, involving BH4 depletion. In the present
study administration of BH4 attenuated decreases in NOx
level in the coronary effluent during reperfusion, whereas
SOD/catalase did not. These findings indicate that the effect
of BH4 on perfusate NO level is due to improved NOS
activity rather than decreased breakdown of NO by super-
oxide anion. Recently, Shen and associates27 have sug-
gested that endogenous NO increases myocardial metabolic
efficiency by reducing myocardial O2 consumption. Thus, a
part of the cardioprotective effects of BH4 might be ex-
plained by the increased generation of NO.
Although it remains unclear why no change in CF was
observed with BH4 after ischemia in spite of increases in
NOx level, it is unlikely that the beneficial effects of BH4
would attribute solely to increased generation of NO be-
cause SOD/catalase exhibited a cardioprotective effect sim-
ilar to that of BH4 without an increase in NOx level.
Therefore, these findings suggest a possibility that reduced
generation of OFRs rather than increased generation of NO
by NOS might be a key mechanism of the cardioprotective
effect of BH4. In this regard recent investigations proposed
that endothelial NOS–dependent superoxide formation
plays an important role in pathologic conditions, such as
diabetes, hypertension, and atherosclerosis,28,29 which
would be related to reduced levels of BH4.7 In addition,
enhancement of NO bioavailability by administration of
BH4 has been reported in patients with hypercholesterol-
emia.22 The current findings imply that supplementary ad-
ministration of BH4, perhaps in combination with L-argi-
nine, free radical scavengers, or both, might provide a novel
strategy to prevent myocardial ischemia-reperfusion injury
and associated complications.
The present data clearly demonstrate that BH4 has car-
dioprotective effects in a rat model of reperfusion injury and
might provide important mechanistic information linking
BH4 to improved cardiac function. However, the precise
mechanism of action of BH4 involved in lessening myocar-
dial ischemia-reperfusion injury remains to be clarified in
this model at present. Further studies, including combined
treatment with BH4 and SOD/catalase, might need to eval-
uate the concise role of BH4 in ischemia-reperfusion injury.
Moreover, experiments with hemoglobin or carboxy-PTIO
or other suitable NO-avid molecules that scavenge NO
might help to evaluate the role of NO in cardioprotection.
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